Cardiff Oncology, Inc. CRDF
We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics. We are focusing our clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), metastatic triple negative breast cancer ("mTNBC") and Chronic Myelomonocytic Leukemia ("CMML"). Our clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593.0K | $683.0K | $488.0K | $386.0K | $359.0K | $366.0K | $244.6K | $378.3K | $505.4K | $381.1K |
| Cost of revenue | — | — | — | — | — | — | $0 | $597.5K | $1.8M | $1.7M |
| Gross profit | — | — | — | — | — | — | $244.6K | -$219.1K | -$1.3M | -$1.3M |
| R&D | — | — | — | $27.1M | $17.4M | $11.2M | — | — | — | — |
| SG&A | $14.2M | $12.5M | $13.0M | $13.2M | $11.8M | $8.2M | $5.8M | $8.0M | $14.2M | $11.5M |
| Total operating expenses | $49.6M | $49.3M | $45.9M | $40.3M | $29.2M | $19.5M | $16.9M | $17.4M | $26.1M | $40.5M |
| Operating income | -$49.0M | -$48.7M | -$45.4M | -$39.9M | -$28.9M | -$19.1M | -$16.7M | -$17.1M | -$25.6M | -$40.1M |
| Interest expense | — | — | — | — | $0 | $2.0K | $0 | $25.4K | $1.0M | $1.7M |
| Pre-tax income | -$45.9M | -$45.4M | -$41.4K | -$38.7M | -$28.3M | -$19.3M | -$16.4M | -$16.5M | -$24.9M | -$39.2M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$45.9K | -$45.4K | -$41.4K | -$38.7M | -$28.3M | -$19.3M | -$16.4M | -$16.5M | -$24.9M | -$39.2M |
| EPS, basic | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | — | -8.26 | -51.76 | -1.30 |
| EPS, diluted | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | -2.80 | -8.26 | -51.76 | -1.37 |
| Shares, diluted (wtd. avg.) | 66.8M | 47.6M | 44.7M | 43.6M | 39.0M | 20.9M | 6.0M | 2.3M | 481,672 | 30.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.5M | $51.5M | $21.7M | $16.3M | $11.9M | $131.0M | $10.2M | $11.5M | $8.2M | $13.9M |
| Short-term investments | $40.8M | $40.3M | $53.2M | $88.9M | $128.9M | $0 | — | — | $0 | $24.0M |
| Receivables | $182.0K | $773.0K | $288.0K | $771.0K | $535.0K | $320.0K | $203.5K | $167.8K | $77.1K | $100.5K |
| Total current assets | $60.1M | $95.1M | $77.4M | $111.3M | $146.1M | $133.4M | $11.4M | $12.8M | $9.5M | $39.0M |
| Property, plant and equipment | $578.0K | $898.0K | $1.2M | $1.3M | $382.0K | $624.0K | $877.8K | $1.3M | $2.4M | $3.8M |
| Total assets | $61.9M | $97.2M | $81.6M | $116.2M | $149.5M | $134.7M | $13.1M | $14.2M | $12.3M | $44.0M |
| Accounts payable | $8.1M | $4.8M | $2.0M | $2.0M | $1.4M | $1.4M | $656.3K | $664.8K | $825.2K | $1.1M |
| Total current liabilities | $16.4M | $13.4M | $10.4M | $7.8M | $6.6M | $6.1M | $4.8M | $2.9M | $3.9M | $7.8M |
| Total liabilities | $16.5M | $14.2M | $11.9M | $9.8M | $9.1M | $6.6M | $5.8M | $4.1M | $5.8M | $24.2M |
| Retained earnings | -$430.0M | -$384.2M | -$339.5M | -$298.1M | -$259.8M | -$231.5M | -$208.9M | -$192.2M | -$173.0M | -$148.1M |
| Total equity | $45.4M | $82.9M | $69.7M | $106.3M | $140.4M | $128.2M | $7.3M | $10.1M | $6.5M | $19.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$37.9M | -$37.7M | -$30.9M | -$33.8M | -$23.0M | -$16.3M | -$13.3M | -$13.2M | -$23.3M | -$31.0M |
| Depreciation and amortisation | $364.0K | $404.0K | $398.0K | $236.0K | $451.0K | $466.0K | $494.2K | $859.5K | $1.2M | $1.1M |
| Stock-based compensation | $5.7M | $4.8M | $4.5M | $4.3M | $3.2M | $1.8M | $884.9K | $2.2M | $4.0M | $7.5M |
| Capital expenditure | $44.0K | $80.0K | $582.0K | $1.0M | $205.0K | $211.0K | $67.6K | $5.1K | $101.1K | $823.5K |
| Investing cash flow | $1.3M | $13.7M | $36.2M | $38.1M | -$131.4M | -$211.0K | -$67.6K | $22.8K | $24.0M | -$24.8M |
| Financing cash flow | $2.6M | $53.8M | $0 | $75.0K | $35.5M | $137.3M | $12.1M | $16.4M | -$6.4M | $2.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213037-26-000006.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $381.1K | $505.4K | $378.3K | $244.6K | $366.0K | $359.0K | $386.0K | $488.0K | $683.0K | $593.0K |
| Gross profit | -$1.3M | -$1.3M | -$219.1K | $244.6K | — | — | — | — | — | — |
| Net income | -$39.2M | -$24.9M | -$16.5M | -$16.4M | -$19.3M | -$28.3M | -$38.7M | -$41.4K | -$45.4K | -$45.9K |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Other event Item 8.01
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Material agreement signed Item 1.01
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |